{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T04:11:56Z","timestamp":1728101516759},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00108-024-01712-4","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T11:03:18Z","timestamp":1725015798000},"page":"1040-1043","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["H\u00e4mophilie\u00a0\u2013 Revolution der Therapiem\u00f6glichkeiten?","Hemophilia: is a\u00a0revolution in treatment options taking place?"],"prefix":"10.1007","volume":"65","author":[{"given":"Michael","family":"Spannagl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"6","key":"1712_CR1","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/jth.14784","volume":"18","author":"F Peyvandi","year":"2020","unstructured":"Peyvandi\u00a0F, Kenet\u00a0G, Pekrul\u00a0I, Pruthi\u00a0RK, Ramge\u00a0P, Spannagl\u00a0M (2020) Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. J\u00a0Thromb Haemost 18(6):1242\u20131255. https:\/\/doi.org\/10.1111\/jth.14784","journal-title":"J Thromb Haemost"},{"key":"1712_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu\u00a0J, Oldenburg\u00a0J, Paz-Priel\u00a0I et\u00a0al (2018) Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N\u00a0Engl J Med 379:811\u2013822","journal-title":"N Engl J Med"},{"key":"1712_CR3","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe\u00a0SW, Shima\u00a0M, Lehle\u00a0M et\u00a0al (2019) Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4\u00a0weeks in people with haemophilia A (HAVEN 4): a\u00a0multicentre, open-label, non-randomised phase\u00a03\u00a0study. Lancet Haematol 6:e295\u2013e305","journal-title":"Lancet Haematol"},{"key":"1712_CR4","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young\u00a0G, Liesner\u00a0R, Chang\u00a0T et\u00a0al (2019) A\u00a0multicenter, open-label phase\u00a03\u00a0study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134:2127\u20132138","journal-title":"Blood"},{"key":"1712_CR5","unstructured":"Hemlibra European Medicines Agency (EMA) Marketing Authorisation 2018. https:\/\/www.ema.europa.eu\/en\/news\/first-class-medicine-prevent-bleeding-haemophilia-patients-inhibitors. Zugegriffen: 20. Nov. 2021"},{"key":"1712_CR6","unstructured":"(2018) Hemlibra Food and Drug Administration (FDA) approval for patients with and without inhibitors. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors. Zugegriffen: 20. Nov. 2021"},{"key":"1712_CR7","unstructured":"Tiede A, Hart C, Kn\u00f6bl P, Greil R, Oldenburg J, Sachs UJ, Miesbach W, Pfrepper C, Trautmann-Grill K, Holstein K, Pilch J, M\u00f6hnle P, Schindler C, Weigt C, Schipp D, May M, Dobbelstein C, Pelzer FJ, Werwitzke S, Klamroth R Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase\u00a02\u00a0study."},{"issue":"10274","key":"1712_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","volume":"397","author":"ME Mancuso","year":"2021","unstructured":"Mancuso\u00a0ME, Mahlangu\u00a0JN, Pipe\u00a0SW (2021) The Changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 397(10274):630\u2013640","journal-title":"Lancet"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01712-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T10:02:13Z","timestamp":1728036133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01712-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01712-4","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"17 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Spannagl gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}